ArticleEuropean heart journal. Case reports2026
Genetic variants in acetylcholine processing and significant improvement with pyridostigmine in a patient with postural orthostatic tachycardia syndrome: a case report.
Article in European heart journal. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postural orthostatic tachycardia syndrome (POTS) is a common autonomic disorder of heterogeneous pathophysiology involving relative sympathetic overactivity and/or parasympathetic hypofunction. Postural orthostatic tachycardia syndrome is characterized by exaggerated postural tachycardia in the absence of orthostatic hypotension, in conjunction with orthostatic intolerance and other cardiovascular and neurologic features. Case summary: We report a 30-year-old woman with POTS who experienced significant improvement with pyridostigmine. The whole genome sequencing demonstrated four single nucleotide polymorphisms-AchE, BChE, PEMT, and CHDH-variants involved in acetylcholine processing that may have led to acetylcholine deficiency and resultant parasympathetic hypofunction with relative sympathetic hyperactivity in this patient. Her Composite Autonomic Symptom Score-31 (COMPASS-31) after initiation of pyridostigmine decreased from 56.15 pre-treatment to 32 post-treatment, which indicated a 43% improvement in autonomic symptom burden, while her daily step count increased from an average of 4000 steps pre- to 7500 steps post-treatment with pyridostigmine. Discussion: We hypothesize that genetic variants in acetylcholine processing may result in acetylcholine deficiency state and may represent one of many pathophysiologic mechanisms of POTS. Whole genome sequencing and validated genetic tests for these and other genetic variants may be valuable diagnostic tools in delineating specific pathophysiology, POTS phenotypes, and personalized treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.